Bill Gates-backed Oxford biotech totals $100M funding to discover new drugs using AI

Exscientia

Oxford-based Exscientia is a clinical-stage pharmatech that uses Artificial Intelligence (AI) to design and discover new drugs. The company just announced that BlackRock’s funds joined its Series C investment round, closing the round at $100 million (nearly £72 million). Back in 2020, the Series C funding round was initiated by existing investors including Novo Holdings, etc.

Read More